

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer:	Nufarm Finance (NZ) Ltd
Name of listed issuel.	` '
Date this disclosure made:	13/11/2015
Date of last disclosure:	8/05/2015
Date of last disclosure.	0/03/2013
Director or senior manager giving disclosure	
Full name(s):	William Bruce Goodfellow
Name of listed issuer:	Nufarm Finance (NZ) Ltd
Name of related body corporate (if applicable):	Nufarm Limited
Position held in listed issuer:	Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives	s)
Class of affected quoted financial products:	Fully Paid Ordinary Shares
Nature of the affected relevant interest(s):	Shares held by Sulkem Company Limited, a company controlled by WB Goodfellow Direct
For that relevant interest-	
Number held in class before acquisition or disposal:	1) 126,493 2) 112,488
Number held in class after acquisition or disposal:	1) 127,400 2) 112,714
Current registered holder(s):	Sulkem Company Limited WB Goodfellow
Registered holder(s) once transfers are registered:	Sulkem Company Limited WB Goodfellow
Summary of acquisition or disposal of specified derivatives relevant interest (if applications)	ble)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates:	2
Details of transactions requiring disclosure-	<u></u>

Date of transaction:	13/11/2015
Nature of transaction:	On Market Trade
Name of any other party or parties to the transaction (if known):	Not Known
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	A\$8.3691 (NZ\$9.00113)
Number of financial products to which the transaction related:	1
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	No
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of guoted financial products:	Fully Paid Ordinary Shares
Nature of relevant interest:	Beneficial interest in shares held by Trustee of Nufarm Non Executive Director Share Plan
For that relevant interest,-	
Number held in class:	31,585
Current registered holder(s):	Pacific Custodians Pty Ltd
Class of quoted financial products:	1) Fully Paid Ordinary Shares 2) NSS - Listed on NZDX
Nature of relevant interest:	Wife
For that relevant interest,-	
i or that relevant interest,-	1) 13,000
Number held in class:	2) 100
Current registered holder(s):	MA Goodfellow
Class of quoted financial products:	Fully Paid Ordinary Shares NSS - Listed on NZDX
	Non beneficial interest as Chairman of the St
Nature of relevant interest:	Kentigern Trust Board
For that relevant interest,-	
	1) 430,434
Number held in class:	2) 19,727
Current registered holder(s):	St Kentigern Trust
Class of quoted financial products:	NSS - Listed on NZDX
olado di quotou ilituriolar produoto.	
Nature of relevant interest:	Shares held by Archem Trading (NZ) Ltd, a company controlled by WB Goodfellow
For that relevant interest,-	
Number held in class:	700
Current registered holder(s):	Archem Trading (NZ) Ltd
Class of quoted financial products:	Fully Paid Ordinary Shares NSS - Listed on NZDX

For that relevant interest,- Number held in class: Current registered holder(s): Class of quoted financial products: Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust For that relevant interest,- Number held in class: Current registered holder(s): Class of quoted financial products: Class of quoted financial products: NSS - Listed on NZDX	Nature of relevant interest:	Non-beneficial interest arising from the holding of Ordinary Shares in Nufarm Limited and Nufarm Step-Up Securities (NSS) in Nufarm Finance (NZ) Limited (which is wholly owned by Nufarm Limited) by trustees of the Goodfellow Foundation. The Goodfellow Foundation is associated with the Goodfellow family, of which WB Goodfellow is Chairman and a member of the Board of trustes.
Number held in class: Current registered holder(s): Class of quoted financial products: Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust For that relevant interest. Number held in class: Current registered holder(s): Class of quoted financial products: Current registered holder(s): Class of quoted financial products: Current registered holder(s): Class of quoted financial products: Nature of relevant interest. Number held in class: Current registered holder(s): Class of quoted financial products: Nature of relevant interest. Number held in class: Current registered holder(s): Auckland Medical Research Foundation Current register		
Number held in class: Current registered holder(s): Class of quoted financial products: Nature of relevant interest: For that relevant interest: For that registered holder(s): Class of quoted financial products: Current registered holder(s): Class of quoted financial products: Current registered holder(s): Class of quoted financial products: Nature of relevant interest. For that relevant interest. For that relevant interest. Current registered holder(s): Current registered holder(s): Current registered holder(s): Every a derivative relevant interest. Type of derivative: Details of derivative: Details of derivative: Details of derivative (if any): A statement as to whether the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the underlying afficial products (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the underlying in affected by the value of the underlying of the under the derivative of the value of the underlying in affected by the value of the underlying in ancial products (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the underlying in affected by the value	For that relevant interest,-	4) 22 054
Ciass of quoted financial products: Ciass of quoted financial products: Fully Paid Ordinary Shares Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust Aumber held in class: Current registered holder(s): Ciass of quoted financial products: NSS - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation Ciass of derivative relevant interest, Type of derivative: Details of derivative; Details of derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the underlying financial products: The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the underlying financial products:	Number held in class:	
Class of quoted financial products: Nature of relevant interest: For that relevant interest: Class of quoted financial products: NSS - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation Nature of relevant interest; For that relevant interest; Number held in class: Current registered holder(s): For a derivative relevant interest, Type of derivative: Details of derivative; The notional value of the derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying prinancial products: Full Paid Ordinary Shares Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust 400,861 WB Goodfellow and Edgar William Preston as Trustees of the 531 Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust WB Goodfellow and Edgar William Preston as Trustees of the Sal Trust		The Goodfellow Foundation
Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust For that relevant interest. Number held in class: Current registered holder(s): Class of quoted financial products: Nature of relevant interest. Number held in class: Class of quoted financial products: Nature of relevant interest. Number held in class: Por that relevant interest. Number held in class: Current registered holder(s): For that relevant interest. Number held in class: Current registered holder(s): For a derivative relevant interest. Type of derivative. Details of derivative. Details of derivative. The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): Expiry date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable underlying financial products: Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust 400,861 WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and Edgar William Preston as Trustees of the S31 Trust WB Goodfellow and E		
Nature of relevant interest: For that relevant interest. Number held in class: Current registered holder(s): Class of quoted financial products: NSS - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation Nature of relevant interest. For that relevant interest. Number held in class: Current registered holder(s): Current registered holder(s): For a derivative relevant interest. Type of derivative. Details of derivative. Details of derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative value of the derivative is affected by the value of the underlying financial products:	Class of quoted financial products:	Fully Paid Ordinary Shares
For that relevant interest Number held in class: Current registered holder(s): Class of quoted financial products: NSS - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation Nature of relevant interest: For that relevant interest Number held in class: Current registered holder(s): Ero a derivative relevant interest,- Type of derivative: Details of derivative. Details of derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative value of the derivative is affected by the value of the underlying financial products:	Nature of relevant interest:	Interest as Trustee with Edgar William Preston as Trustees of the 531 Trust
Number held in class: Current registered holder(s): Class of quoted financial products: Nature of relevant interest: For that relevant interest. Current registered holder(s): Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- The notional value of the derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative value of the derivative is affected by the value of the underlying financial products: WB Goodfellow and Edgar William Preston as Trustees of the 531 Trust WB Goodfellow and Edgar William Preston as Trustees of the 531 Trust WB Goodfellow and Edgar William Preston as Trustees of the 531 Trust WB Goodfellow and Edgar William Preston as Trustees of the 531 Trust Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation YB S - Listed on NZDX Auckland Medical Research Foundation YB S - S - S - S - S - S - S - S - S - S	For that relevant interest -	
Current registered holder(s): Class of quoted financial products: Nature of relevant interest: For that relevant interest. Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the aderivative is affected by the value of the underlying financial products: Trustees of the 531 Trust Member of the Board of Trustees of the Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation 27,508 Auckland Medical Research Foundation 28,558 Auckland Medical Research Foundation 29,558 Auckland Medical Research Foundation 20,558 Auckland Medical Research Foundation	·	400,861
Class of quoted financial products: NSS - Listed on NZDX Member of the Board of Trustees of the Auckland Medical Research Foundation Por that relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative; Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		_
Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative; Details of derivative,- The notional value of the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative of the value of the derivative is affected by the value of the underlying financial products: Member of the Board of Trustees of the Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation	Current registered holder(s):	Trustees of the 531 Trust
Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: Medical Research Foundation 26,558 Auckland Medical Research Foundation 26,558 Auckland Medical Research Foundation	Class of quoted financial products:	NSS - Listed on NZDX
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Nature of relevant interest:	Member of the Board of Trustees of the Auckland Medical Research Foundation
Current registered holder(s): For a derivative relevant interest,- Type of derivative; Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	For that relevant interest,-	
Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Number held in class:	26,558
Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Current registered holder(s):	Auckland Medical Research Foundation
Type of derivative: Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		
Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	·	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		
products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	·	
Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	, ,,	
Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	A statement as to whether the derivative is cash settled or physically settled:	
The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Maturity date of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Expiry date of the derivative (if any):	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:		
For that derivative relevant interest,-	under the derivative or the value of the derivative is affected by the value of the	
	For that derivative relevant interest,-	
Parties to the derivative:	Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:	
Date of signature:	13/11/2015
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.